Welcome to our dedicated page for NUREXONE BIOLOGIC news (Ticker: NRXBF), a resource for investors and traders seeking the latest updates and insights on NUREXONE BIOLOGIC stock.
NurExone Biologic Inc. (NRXBF) news focuses on its progress as a preclinical biotechnology company developing regenerative exosome-based therapies for central nervous system injuries. The company’s updates highlight advances in its lead candidate ExoPTEN, exosome manufacturing capabilities, regulatory milestones, intellectual property, and financing activities that support its development plans.
Readers following NurExone’s news can see detailed reports on preclinical data, including dose-dependent recovery of visual function in glaucoma and optic nerve injury models and motor recovery in acute spinal cord injury models. The company also publishes laboratory analyses showing anti-inflammatory activity of its exosomes and higher biological activity compared with commercially available exosome products, which it presents as strengthening the rationale for its platform.
News releases also cover regulatory and scientific visibility, such as Orphan Drug Designation for ExoPTEN in acute spinal cord injury and invited presentations at international conferences on exosomes, regenerative medicine, and bioprocessing. These items provide insight into how NurExone is engaging with regulators and the scientific community around exosome-based therapeutics.
On the corporate side, NurExone reports on patent developments, including a U.S. Notice of Allowance and an Israeli patent grant for its exosome manufacturing process, as well as its participation in programs like ARMI’s BioFab Startup Lab. Investors can also track capital raises, warrant exercises, and private placements that fund R&D, manufacturing initiatives, and U.S. expansion through its subsidiary Exo-Top Inc., including plans for a commercial exosome production facility in Indianapolis, Indiana.
For anyone monitoring NRXBF, this news stream offers a consolidated view of scientific results, manufacturing readiness, regulatory positioning, and financial developments that shape NurExone’s trajectory in exosome-based CNS therapies.
NurExone Biologic announces the Japan Patent Office's issuance of a Notice of Allowance for the ExoPTEN patent, which covers innovative extracellular vesicles comprising a PTEN inhibitor. The ExoPTEN drug aims to promote nerve growth and regeneration after acute spinal cord injury. This patent, licensed from Technion, marks a significant step for NurExone's technology in the Asian market and follows corresponding approvals in the USA and Russia. Additionally, the company extended its investor relations agreement with BullVestor Medien until May 2025, aiming to boost awareness in German-speaking countries.
NurExone has announced the appointment of Dr. Ram Petter as a consultant to drive strategic collaborations. Dr. Petter brings extensive experience from his tenure at Teva Pharmaceuticals. His role will focus on aiding NurExone's partnerships and licensing agreements, enhancing the Company's operational activities, and supporting the ExoTherapy platform for drug delivery beyond acute spinal cord injury. This move aims to foster innovation and commercial partnerships to realize NurExone's vision for regenerative medicine.
Summary not available.